source
- Merck reports positive mid-stage results for Hanmi-licensed MASH drugMerck announced Thursday that its dual GLP-1/glucagon agonist, which it licensed from South Korea’s Hanmi Pharmaceutical in 2020, has met its primary endpoints in a mid-stage trial for metabolic dy…
- Gubra aims to expand beyond obesity drugs, targets first portfolio partner this yearCopenhagen‑based biotech Gubra is currently known for its obesity drug candidates, but the company says its long‑term growth will depend on a broader pipeline beyond metabolism. The firm’s existin…